GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,954 DKK | +2.04% |
|
-2.57% | -9.30% |
| 04-16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| 04-16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Chart calendar Genmab A/S
d76bacfbeff11c22194e31a4522682.nQWTn-cwgNo9-NAcVH7iUdnG5Fndff9t9OGtmoUxt5M.7ne-7KAI7oBLjYJ9ADekCZGUhRq0FqU7joSe7MtZweHpZurlhVnComyzow~57ce80de300723d1e84a8c6dfb102ee6
Upcoming events on Genmab A/S
Past events on Genmab A/S
| 03/04/2024 12:00 | Acquisition of ProfoundBio by Genmab A/S Call |
| 13/03/2024 13:00 | Annual General Meeting |
| 05/03/2024 | TD Cowen Health Care Conference |
| 27/02/2024 | UBS European Healthcare Conference |
| 14/02/2024 17:00 | Q4 2023 Earnings Call |
| 14/02/2024 16:02 | Q4 2023 Earnings Release |
| 10/01/2024 19:15 | JPMorgan Healthcare Conference |
| 12/12/2023 16:00 | R&D Day |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number 5089 |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number 4757 |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number 5158 |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number 4481 |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number 4457 |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number 3135 |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number 3092 |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number 3053 |
| 10/12/2023 17:30 | American Society of Hematology Meeting - Abstract Number 438 |
| 10/12/2023 01:30 | American Society of Hematology Meeting - Abstract Number 1655 |
| 10/12/2023 01:30 | American Society of Hematology Meeting - Abstract Number 1729 |
| 10/12/2023 01:30 | American Society of Hematology Meeting - Abstract Number 1733 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million DKK | Released Forecast Spread | 5 366 5 159 4.02% | 10 111 9 843 2.72% | 8 482 8 376 1.26% | 14 595 14 068 3.75% | 16 474 16 380 0.58% | 19 660 |
|
EBITDA Million DKK | Released Forecast Spread | 2 777 2 460 12.89% | 6 572 6 099 7.75% | 3 266 3 111 4.98% | 6 719 6 371 5.46% | 5 616 5 721 -1.83% | 6 410 |
|
EBIT Million DKK | Released Forecast Spread | 2 638 2 317 13.83% | 6 313 5 967 5.79% | 3 018 2 960 1.96% | 6 357 6 008 5.81% | 5 321 5 398 -1.42% | 6 044 |
|
Earnings before Tax (EBT) Million DKK | Released Forecast Spread | 2 859 2 645 8.11% | 5 904 5 723 3.17% | 3 983 3 731 6.77% | 7 035 8 905 -21% | 5 637 6 236 -9.6% | 6 598 |
|
Net income Million DKK | Released Forecast Spread | 2 166 2 085 3.89% | 4 758 4 706 1.1% | 3 008 2 847 5.64% | 5 522 6 793 -18.71% | 4 352 4 989 -12.77% | 5 106 |
|
EPS DKK | Released Forecast Spread | 34,0 32,8 3.61% | 72,2 69,4 4.06% | 45,5 43,8 3.94% | 83,7 104 -19.22% | 66,0 76,2 -13.35% | 78,1 |
| Announcement Date | 19/02/20 | 23/02/21 | 16/02/22 | 22/02/23 | 14/02/24 | - |
Quarterly results
| Fiscal Period | December | 2020 S1 | 2021 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million DKK | Released Forecast Spread | 6 343 6 164 2.9% | 3 553 3 224 10.2% | 2 619 2 538 3.19% | 2 119 2 074 2.15% | 3 162 2 833 11.6% | 5 281 5 136 2.82% | 4 087 3 634 12.46% | 5 227 4 727 10.57% | 2 854 2 809 1.62% | 4 198 4 070 3.13% | 7 052 6 896 2.26% | 4 744 4 474 6.03% | 4 678 4 610 1.48% | 3 987 | 4 964 | 9 117 | 5 280 | 5 429 | 4 715 |
|
EBITDA Million DKK | Released Forecast Spread | 4 583 4 480 2.3% | 1 345 980 37.24% | 1 016 776 30.87% | 529 358 47.73% | 1 263 1 312 -3.74% | 1 792 1 951 -8.15% | 1 953 1 583 23.36% | 2 974 2 708 9.84% | 458 583 -21.48% | 1 520 1 670 -8.96% | 1 978 2 145 -7.79% | 1 739 1 646 5.65% | 1 899 1 804 5.28% | 880 | 1 656 | 2 815 | 1 820 | 1 824 | 975 |
|
EBIT Million DKK | Released Forecast Spread | 4 568 4 389 4.08% | 1 319 864 52.66% | 809 772 4.76% | 514 442 16.3% | 1 247 1 156 7.87% | 1 761 1 814 -2.92% | 1 931 1 541 25.34% | 2 665 2 314 15.17% | 437 527 -17.08% | 1 497 1 573 -4.85% | 1 934 1 977 -2.18% | 1 717 1 702 0.87% | 1 670 1 772 -5.73% | 831 | 1 607 | 2 630 | 1 763 | 1 789 | 920 |
|
Earnings before Tax (EBT) Million DKK | Released Forecast Spread | 4 682 4 682 0% | 1 846 1 759 4.95% | 966 772 25.06% | 612 499 22.59% | 2 489 1 183 110.39% | 3 101 1 932 60.51% | 3 272 1 584 106.63% | 662 2 199 -69.9% | 286 402 -28.85% | 1 723 1 602 7.57% | 2 009 1 927 4.26% | 2 702 1 774 52.33% | 926 1 888 -50.95% | 1 064 | 1 845 | 2 876 | 1 861 | 1 802 | 817 |
|
Net income Million DKK | Released Forecast Spread | 3 647 4 573 -20.25% | 1 402 1 372 2.19% | 716 603 18.69% | 465 357 30.19% | 1 891 913 107.1% | 2 356 1 469 60.38% | 2 582 1 187 117.46% | 584 1 556 -62.47% | 226 397 -43.08% | 1 357 1 204 12.72% | 1 583 1 503 5.32% | 2 129 1 382 54.01% | 640 1 439 -55.52% | 832 | 1 411 | 2 215 | 1 439 | 1 415 | 638 |
|
EPS DKK | Released Forecast Spread | 55,5 70,2 -20.91% | 21,3 20,9 1.67% | 10,8 9,25 16.99% | 7,05 5,39 30.88% | 28,7 13,8 106.99% | 35,7 22,1 61.58% | 39,2 18,3 113.88% | 8,82 23,2 -61.91% | 3,43 5,07 -32.28% | 20,6 19,3 7.03% | 24,0 22,7 5.86% | 32,3 21,2 52.42% | 9,67 23,0 -57.93% | 12,8 | 22,4 | 34,2 | 22,3 | 23,3 | 23,7 |
| Announcement Date | 12/08/20 | 11/08/21 | 16/02/22 | 11/05/22 | 10/08/22 | 10/08/22 | 09/11/22 | 22/02/23 | 10/05/23 | 03/08/23 | 03/08/23 | 07/11/23 | 14/02/24 | - | - | - | - | - | - |
More events
Past sector events for Genmab A/S
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- GMAB Stock
- Calendar Genmab A/S
